During the ACR Convergence 2020 Opening Session on Thursday, ACR President Ellen M. Gravallese, MD, talked about how the specialty’s response during the pandemic has provided great hope and will help rheumatology become an even more essential specialty.
Not all osteoporosis patients are good candidates for a drug holiday. But for some patients, a holiday reduces the risk of rare side effects along with the burdens of paying for and taking osteoporosis medications.
Many patients have seen biologics turn RA, psoriasis, lupus, and other familiar disorders into manageable chronic conditions with occasional flares. But the path from research to treatment is neither swift nor direct.
Rheumatologists at some point may be asked to consult and evaluate children with central nervous system (CNS) dysfunction related to anautoinflammatory disease, and a session at ACR Convergence 2020 will help rheumatologists learn how to offer needed support.
MEET THE POSTER PRESENTER: In SLE, HCQ greatly reduces lupus flares, but long term, this drug may cause irreversible retinal damage leading to vison loss, and there is no treatment for HCQ retinal toxicity other than discontinuing the drug to prevent further damage.
MEET THE POSTER PRESENTER: This global Phase IIb, randomized, double-blind, placebo-controlled study evaluated the efficacy, dose response, and safety of evobrutinib compared with placebo in adult patients with active autoantibody-positive SLE who received standard of care therapy.
MEET THE POSTER PRESENTER: Iberdomide is a small molecule, high-affinity ligand of cereblon that has immunomodulatory properties and is currently in development for the treatment of systemic lupus erythematosus (SLE) and multiple myeloma.